1. The Gao, Jie, et al. "Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China." The Lancet (2025).
2. Markelov, Vladislav, et al. "Scalable and ultrafast CAR-T cell production using microfluidics." Lab on a Chip 25.12 (2025): 3005-3015
3. Yang, Chen, et al. "A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity." Cell Reports Medicine 6.10 (2025).
4. Hui, Xinhui, et al. "GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint." Science Advances 11.10 (2025): eadr9395.
5. Chen, Zhaozhao, et al. "mRNA‐laden lipid nanoparticle‐enabled humanized CD19 CAR‐T‐cell engineering for the eradication of leukaemic cells." British Journal of Haematology 206.2 (2025): 628-643.
6. Stepanyan, Nara G., et al. "NK-cell therapy after allogeneic hematopoietic stem cell transplantation in patients with acute leukemias." Cellular Therapy and Transplantation 13.4 (2024): 31-36
7. Nenashëva, Tatyana Anatol’yevna, et al. “Comparison of the functional and immunophenotypic profile of anti-CD19-modified T-cells expressing a chimeric antigen receptor, derived from healthy donors and patients with B-cell acute lymphoblastic leukemia, during prolonged in vitro restimulation.” Hematology and Transfusiology 2 (70) (2025): 156-164.
8. Chen, Min, et al. "Identification of ENTPD1 as a novel biomarker linking allergic rhinitis and systemic lupus erythematosus." Scientific Reports 14.1 (2024): 18266.
9. Hui, Xinhui, et al. "A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma." Frontiers in Immunology 15 (2024): 1462076.
10. Xiong, Ying, et al. "Technological and manufacturing innovation drive improved access to engineered T cell therapies." Medical Research Archives 11.11 (2023).
显示更多
关闭
